Abstract: A pharmaceutical preparation for the prevention and treatment of blood coagulation disorders is described which is characterized in that it comprises Factor V as a native protein, derivative and/or fragment thereof and Protein S in suitable pharmaceutical carrier.

Abstract: There is disclosed an anti-plasma antibody preparation for treatment of a mammal, which preparation is capable of directly or indirectly inhibiting and/or eliminating several blood factors, a method of producing such a preparation and a method of evaluating substances for treating clotting disorders by using said anti-plasma antibody preparation. There is further disclosed a method of determining the bleeding characteristics of a mammal.

Abstract: Proenzymes or proforms of blood factors can be cleaved in the presence of a detergent or a chaotropic substance to produce active blood factors selected from the group consisting of Factor Va, Factor VIIa, Factor VIIIa, Factor IXa, Factor Xa, Factor XIa, Factor XIIa, Factor XIIIa and activated protein C. The chaotropic substance can be urea, guanidinium hydrochloride or a thiocyanate salt. Under these conditions, proteolytic activation occurs in a controlled and restricted manner. Consequently, it is possible to isolate high yields of active blood factor, while minimizing the production of inactive degradation products. Immobilization of the proenzyme or proform on a solid support prior to activation facilitates the separation of active blood factor from the proenzyme or proform and inactive peptide fragments.

Abstract: There is disclosed a method of quantitating nucleic acids in a sample by using nucleic acid amplification, wherein, prior to the amplification step, a given amount of a known nucleic acid molecule is added to the sample as internal standard, which standard nucleic acid molecule differs from the nucleic acid to be quantitated by at least one detectable characteristic; to obtain a high precision and good reproducibility, known amounts of at least two known nucleic acid molecules which differ from each other and from the nucleic acid to be quantitated in at least one detectable characteristic are added as an internal standard to the sample prior to nucleic acid amplification, the amounts of amplified sample and standard nucleic acids obtained are determined, and from the amounts obtained, the amount of the nucleic acid to be quantitated originally present in the sample is determined.

Abstract: The invention provides compositions having thrombolytic effects, and comprise plasmin and a plasminogen activator. Such compositions can be administered locally or systemically. The invention also provides simple and safe therapies for thrombotic states and prevention of such states.

Abstract: The invention relates to a pharmaceutical preparation comprising a plasma protein wherein said preparation is free of infectious agents as well as essentially free of denaturation products and is obtainable by a method that encompasses the following steps:a) addition of a polyether and a chaotropic agent to a solution comprising the plasma protein, optional lyophilization of the solution;b) inactivation of infectious agents in the presence of the polyether by a physio-chemical or chemical treatment, andc) removal of the polyether and the chaotropic agent.

Abstract: Defective poxviruses that lack a function imparted by an essential region of its parental poxvirus are provided for protein production and vaccination. A DNA polynucleotide encoding a protein is inserted into the defective poxvirus and placed under transcriptional control of a promoter. The defective poxvirus is viable when the lost function of the essential region is complemented by a host cell, transgenic animal or helper virus.

Abstract: Defective poxviruses that lack a function imparted by an essential region of its parental poxvirus are provided for protein production and vaccination. A DNA polynucleotide encoding a protein is inserted into the defective poxvirus and placed under transcriptional control of a promoter. The defective poxvirus is viable when the lost function of the essential region is complemented by a host cell, transgenic animal or helper virus.

Abstract: In a method of producing a virus-safe biological preparation by heating while preserving a least 50% of its biologic activity, a biologially compatible tenside is added to the preparation before heating and heating is carried out in the presence of the same, whereupon the tenside, preferably, is eliminated.

Abstract: The invention resides in a matrix, i.e. in a carrier material, with human or animal cells adherently bound thereto, the cells being infected with virus. It has shown that surface-dependent cells suitable for virus propagation remain adherently bound to a matrix even in the virus-infected state, continuously produce virus antigen over relatively long periods of time and deliver them into the culture medium. For producing TBE virus antigen by growing tick-borne encephalitis (TBE) virus in cell cultures, a surface-dependent permanent cell line, preferably the Vero cell line ATCC CCL 81, is inoculated with TBE virus, and the cells are kept bound to carriers in a non-lyric serum-free system while maintaining the cell growth, so as to maintain antigen formation, whereupon the antigen-containing medium is separated form the carrier-bound cells and, in a known manner, is processed to a galencially acceptable preparation by concentration, inactivation and purification.

Abstract: A thrombin of human or animal origin is free of infectious agents and is produced by activation of prothrombin subjected to a heat treatment for the inactivation of infectious agents.

Abstract: The invention relates to a stable preparation which comprises a protein that is bound in and/or on lipid vesicles and that was treated for the inactivation of potentially present viruses. Further, the invention relates to methods for the production of a stable preparation for the treatment of blood coagulation disorders, wherein a protein is bound in and/or on lipid vesicles, and the method comprises a step in which the protein lipid complex is subjected to a treatment for the inactivation of potentially present viruses.

Abstract: An improved method is described to prepare recombinant fowlpox virus for the expression of proteins or for use as a vaccine. The new method uses for the insertion of foreign DNA an intergenic region which is located between the FPV thymidine kinase (tk)gene and the 3'-open reading frame. Said intergenic region is enlarged to comprise one or more unique restriction sites, thereby allowing insertion of foreign DNA in such a way that the FPV tk-gene remains intact and codes for the entire thymidine kinase. New strong poxvirus promoters are presented and new FPV host virus strains carrying a vaccinia virus thymidine kinase gene and an E. coli lacZ gene as a novel non-essential site. The novel fowlpox virus host strains allow the use of any insertion plasmid carrying vaccinia virus tk-gene flanking regions.

Abstract: There is disclosed an apparatus for applying a multiple component tissue adhesive, which apparatus has component conveying channels for the components of the tissue adhesive, extending in a one-piece construction part from a connecting part to a delivery part, and a gas conveying channel for a medicinal gas serving for atomizing the tissue adhesive components, wherein all the conveying channels end in separate exit openings at a front side of the delivery part and extend parallel to one another over at least that part of their longitudinal extension which is immediately upstream of the exit openings, and wherein the component conveying channels together are enclosed by the gas conveying channel at least on that part of their longitudinal extension immediately in front of their exit openings.

Abstract: In a method of producing a virus-safe biological preparation by heating while preserving a least 50% of its biologic activity, a biologially compatible tenside is added to the preparation before heating and heating is carried out in the presence of the same, whereupon the tenside, preferably, is eliminated.

Abstract: A method for the separation of vitamin K-dependent proteins from non-vitamin K-dependent accompanying proteins is described wherein the method is characterized in that at least anion exchange chromatography and optionally affinity chromatography is carried out as well. The method is suitable especially for the purification of Factor II, VII, IX, X as well as Protein S, Protein C and Protein Z. With the aid of the method according to the invention a vitamin K-dependent protein is obtained which is present at a purity of 95%.

Abstract: This invention is directed to a method of evaluating viral reduction capability of a viral inactivation step in a viral inactivation procedure. The method requires spiking a biological product with a virus more than once during the viral inactivation step so that a virus reduction factor can be calculated.

Abstract: The present invention relates to a virus-safe blood coagulation factor XIII preparation, which is obtained by heating an aqueous solution containing the blood coagulation factor XIII having a specific activity of at least 2 U/mg of total protein, wherein the solution containing less than 10% of known stabilizers selected from the group consisting of sugars, polyols, amino acids, peptides and carboxylic acids, as well as less than 0.5 mol ammonium sulfate per liter, wherein the heating is effected for a period of time sufficient to inactivate infectious agents, preferably for a period of time of from 30 min to 100 h.

Abstract: A stable, highly concentrated intravenously tolerable immunoglobulin preparation is described having an immunoglobulin content from 13.5 to 17.5% (w/v), an osmolarity from 250 to 600 mOs/l and a viscosity of no more than 9 cP. The immunoglobulin preparation possesses an exceptional imperishability and also is used as a highly concentrated preparation without problems due to its low viscosity.

Abstract: A treatment of ischemia and the attendant reperfusion injury entails the administration plasmin and plasmin-forming proteins, including lys-plasminogen and similar substances. Lys-plasminogen, which can be obtained from the proteolytic cleavage of glu-plasminogen, has been found to have a protective effect on tissue that has been injured by ischemic conditions. The administration of lys-plasminogen alone, in a dosage of about 10-1000 caseinolytic units/kg, can be used to treat subjects during the time of reperfusion and after reperfusion has already occurred. Lys-plasminogen also can be administered in conjunction with clot lysis therapies, such as those that employ tissue plasminogen activator and the like. Lys-plasminogen can also lessen cerebral edema which results from cerebral ischemia.